Welcome to our dedicated page for TENET HEALTHCARE SEC filings (Ticker: THC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TENET HEALTHCARE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TENET HEALTHCARE's regulatory disclosures and financial reporting.
TENET HEALTHCARE CORP (THC) has a notice of proposed sale under Rule 144 filed on behalf of director Richard J. Mark. The filing covers the potential sale of 10,000 shares of common stock through Fidelity Brokerage Services LLC on the NYSE. Listed share amounts arise from multiple restricted stock vesting compensation awards scheduled between May 2024 and May 2026.
Tenet Healthcare Corporation (THC) announced a private placement of $2.0 billion aggregate principal amount of 6.250% senior notes due September 15, 2034, upsized from a previously announced $1.5 billion offering. Completion is expected on September 22, 2026, subject to customary closing conditions.
Tenet plans to use the net proceeds, together with cash on hand, to redeem $1.5 billion of its 5.125% senior secured first lien notes due November 2027 and $0.5 billion of its 6.125% senior notes due October 2028, with redemptions expected on September 23, 2026. The new notes will be unsecured senior obligations, ranking pari passu with other senior unsecured debt, senior to subordinated obligations, effectively subordinated to secured debt to the extent of collateral value, and structurally subordinated to obligations of subsidiaries.
TENET HEALTHCARE CORPORATION (THC) is reported to have 8,083,830 shares of its common stock beneficially owned by BlackRock, Inc. under an amended Schedule 13G filing. As of August 31, 2026, this position represents 10.0% of Tenet Healthcare’s common stock outstanding.
BlackRock reports sole voting power over 7,837,557 shares and sole dispositive power over all 8,083,830 shares, with no shared voting or dispositive power. Various underlying clients or accounts have rights to dividends or sale proceeds, but no single person has more than five percent of Tenet Healthcare’s outstanding common shares.
TENET HEALTHCARE CORP (THC) director Nadja West reported selling 1,152 shares of common stock on September 2, 2026 in a sale described as an open market or private transaction at $258.80 per share. After this transaction, she reported directly holding 23,653 shares of Tenet Healthcare common stock. No Rule 10b5-1 trading plan is reported.
TENET HEALTHCARE CORP (THC) director Nadja Y. West has filed a notice of proposed sale under Rule 144 for up to 1,152 shares of Tenet common stock through Fidelity Brokerage Services LLC on or after September 2, 2026, to be sold on the NYSE.
The shares derive from restricted stock vesting awards from the issuer, including 978 shares that vested on May 23, 2025 and 174 shares that vested on May 26, 2026, reported as compensation. No other sales are listed for the prior three months.
TENET HEALTHCARE CORP (THC) executive Lisa Y. Foo, EVP and Chief Operating Officer, reported selling 24,000 shares of common stock on August 31, 2026, in an open-market transaction at a weighted average price of $266.32 per share. After these sales, she directly holds 8,053 shares of Tenet Healthcare common stock. The shares were sold in multiple trades at prices ranging from $266.02 to $266.95 per share.
TENET HEALTHCARE CORP (THC) director Cecil D. Haney reported a charitable transfer of company stock. On 2026-08-28, he made a bona fide gift of 150 shares of Tenet Healthcare common stock, with no sale proceeds received, to a charitable donor advised fund. Following this transaction, he directly holds 12,403 shares of Tenet Healthcare common stock.
TENET HEALTHCARE CORP (THC) received a Rule 144 notice from officer Lisa Foo for a proposed sale of up to 24,000 shares of common stock through Fidelity Brokerage Services LLC on or about August 31, 2026. The shares, with an aggregate market value of $6,391,579.07, relate to restricted stock vesting as compensation on several dates in 2025 and 2026. The notice also reports that Foo sold 10,000 shares on July 29, 2026 for $2,580,295.03, and that 80,519,000 shares of Tenet common stock are outstanding.
TENET HEALTHCARE CORP (THC) reported that director Cecil D. Haney sold 1,300 shares of common stock on 2026-08-24. The sale was reported as a non-derivative transaction in an open market or private transaction at a price of $278.03 per share, leaving him with 12,553 directly held shares. The Rule 10b5-1 checkbox was left unchecked, and no footnotes were provided.
TENET HEALTHCARE CORP (THC) reported that CEO and director Saumya Sutaria sold a total of 100,000 shares of common stock in open-market or private transactions on August 24–25, 2026. The sales occurred at weighted-average prices with trade ranges between $272.65 and $279.14 per share, and detailed price breakdowns are available upon request.